Andrei Pikalov, MD, PhD

Lurasidone and Anxiety Symptoms in Bipolar Depression

June 7, 2023

Lurasidone was superior to placebo at reducing anxiety in bipolar depression. Change in anxiety symptoms was predicted by sleep disturbance at baseline.

Joseph F. Goldberg, Cynthia Siu, Michael Tocco, et al

Original Research

Lurasidone and Sexual Function

August 7, 2018

As you probably know, sexual dysfunction is a common side effect of antidepressants and antipsychotics. This secondary analysis of an RCT examines whether the atypical antipsychotic lurasidone was linked...

Anita H. Clayton, Joyce Tsai, Yongcai Mao, et al

Original Research

Lurasidone in Older Adults With Bipolar Depression

October 26, 2016

Lurasidone's favorable safety profile in younger adults suggests it would be a good candidate for the treatment of episodes of bipolar depression in older adults. For your patients 55...

Martha Sajatovic, Brent P. Forester, Joyce Tsai, et al

Original Research

Lurasidone and Bipolar Depression

April 22, 2015

Read the analysis of a randomized placebo-controlled trial of Lurasidone in the Treatment of Bipolar Depression With Mixed (Subsyndromal Hypomanic) Features.

Roger S. McIntyre, Josephine Cucchiaro, Andrei Pikalov, et al

Original Research

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

March 13, 2013

Stephen M. Stahl, Josephine Cucchiaro, Doreen Simonelli, et al

Original Research

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

January 15, 2013

Joseph P. McEvoy, Leslie Citrome, David Hernandez, et al

Original Research

Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

May 4, 2010

David E. Kemp, Joseph R. Calabrese, Quynh-Van Tran, et al

Original Research

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

December 17, 2009

J. Craig Nelson, Michael E. Thase, Madhukar H. Trivedi, et al

Original Research

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

October 15, 2009

John M. Kane, Christoph U. Correll, Donald C. Goff, et al

Original Research

Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics

April 21, 2009

John M. Kane, Wolfgang W. Fleischhacker, Lars Hansen, et al

Original Research

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

December 31, 2008

Madhukar H. Trivedi, Michael E. Thase, Maurizio Fava, et al

Original Research

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

December 15, 2008

Michael E. Thase, Madhukar H. Trivedi, J. Craig Nelson, et al

Lurasidone and Anxiety Symptoms in Bipolar Depression

Lurasidone and Sexual Function

Lurasidone in Older Adults With Bipolar Depression

Lurasidone and Bipolar Depression

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

ELSEWHERE:

FOLLOW US:

Andrei Pikalov, MD, PhD

Lurasidone and Anxiety Symptoms in Bipolar Depression

Lurasidone and Sexual Function

Lurasidone in Older Adults With Bipolar Depression

Lurasidone and Bipolar Depression

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles